ERBB2 and neoplasm: Early research has demonstrated that HER-2/ErbB-2 overexpression is linked to a poor prognosis, and the capacity of HER2-specific antibodies to direct HER2 into CBL-dependent endocytosis and degradation pathways is related to their anti-tumor effects (Li et al., 2007).